Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dexmethylphenidate hydrochloride
Drug ID BADD_D00631
Description Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181]. The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture[A177181].
Indications and Usage Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment[A177187,Label].
Marketing Status approved; investigational
ATC Code N06BA11
DrugBank ID DB06701
KEGG ID D03721
MeSH ID D064699
PubChem ID 154100
TTD Drug ID D02QCD
NDC Product Code 0781-2686; 11014-0316; 60274-710; 0078-0382; 0115-1684; 43602-332; 43602-333; 49884-048; 49884-539; 57664-379; 57664-622; 57664-624; 70010-009; 0527-8106; 0781-2688; 10702-108; 16714-567; 27808-091; 27808-093; 0115-1682; 42858-225; 43386-862; 43602-327; 57664-626; 63629-2175; 63629-2177; 63629-9469; 70010-005; 72162-1472; 72162-1503; 0781-2687; 11014-0314; 60274-720; 10702-107; 0078-0381; 0078-0431; 0078-0432; 0078-0433; 0093-5562; 42858-410; 43602-330; 43602-331; 57664-378; 63629-2173; 63629-2174; 70010-008; 70010-010; 70010-011; 57664-629; 0527-8109; 0527-8110; 0527-8111; 72162-1502; 53834-201; 0078-0609; 16714-566; 0093-5046; 0093-5553; 27808-092; 31722-229; 0115-1683; 0115-1685; 0115-1709; 49884-090; 57664-376; 57664-625; 72162-1493; 0781-2684; 11014-0080; 11014-0211; 11014-0213; 31722-234; 31722-236; 49884-248; 63629-2176; 63629-2178; 63629-2306; 63629-2307; 67877-655; 67877-656; 70010-007; 0527-8113; 72162-1473; 72162-1507; 0781-2683; 0781-2685; 60274-730; 16714-568; 43602-334; 57664-628; 63629-2172; 63629-9467; 70010-006; 0527-8108; 72162-1496; 11014-0103; 11014-0212; 60274-705; 0078-0434; 0078-0493; 0093-5550; 0115-9918; 0115-9920; 42858-011; 43602-328; 49884-333; 67877-657; 0527-8107; 0781-2682; 0781-2689; 17180-1725; 0078-0380; 0078-0430; 0093-5552; 0115-9921; 0115-9922; 43386-861; 43602-329; 49884-339; 49884-546; 57664-623; 63629-2305; 70010-004; 11014-0317; 10702-106; 16714-562; 0093-5045; 31722-230; 31722-233; 0115-1686; 0115-1710; 0115-9919; 43386-860; 63629-2171; 63629-9468; 0527-8112; 72162-1488; 0792-0619; 11014-0315; 11014-0318; 60274-715; 60274-725; 60274-735; 60274-740; 0078-0608; 16714-563; 16714-564; 16714-565; 16714-569; 0093-5551; 0093-5554; 31722-231; 31722-232; 31722-235; 49884-049; 57664-621
UNII 1678OK0E08
Synonyms Dexmethylphenidate Hydrochloride | Hydrochloride, Dexmethylphenidate | Focalin XR | XR, Focalin | Dexmethylphenidate | Focalin
Chemical Information
Molecular Formula C14H20ClNO2
CAS Registry Number 19262-68-1
SMILES COC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersensitivity10.01.03.003--
Immune system disorder10.02.01.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Irritability19.04.02.013; 08.01.03.011--
Laryngeal pain22.12.03.010--
Leukopenia01.02.02.001--Not Available
Mood swings19.04.03.001--Not Available
Muscle twitching15.05.03.005--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.005--Not Available
Palpitations02.11.04.012--
Priapism24.04.12.007; 21.03.01.005--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Tachycardia02.03.02.007--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Tourette's disorder19.11.04.002; 17.19.02.001; 03.10.01.001--Not Available
Urticaria10.01.06.001; 23.04.02.001--
Vasculitis necrotising24.12.04.029; 10.02.02.008--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages